Brain haemorrhage patients offered better treatment

An international trial has provided surgeons with a formula which predicts when brain haemorrhage patients need surgery for the best outcome.

Brain haemorrhage affects some 4 million a year worldwide and the trial, run from Newcastle University, will help to ensure the best treatment is given at the right time.

David Mendelow, Professor of at Newcastle University and honorary consultant within the Newcastle Hospitals NHS Foundation Trust, who ran the trials, has devised a formula published today in The Lancet online which will allow surgeons to calculate when to intervene with surgery after an intracerebral haemorrhage. This occurs when the blood escapes from the into the brain itself to produce a solid clot.

Professor Mendelow said: "This study gives hope to patients at the time of their initial haemorrhagic stroke. Not only will some lives be saved, but we have shown that operating at the right time means that about one in five patients are able to regain their independence."

The results of the trial, known as STICH II (Surgical Trial in Lobar Intracerebral Haemorrhage) are published in The Lancet online and presented today at the European Stroke Conference in London. The , co-ordinated and completed at the Newcastle University Neurosurgery Unit involved 601 patients from 78 centres in 27 countries around the world.

Prior to this trial, surgeons did not have the detailed information telling them which patients benefited the most from surgery. Now this research provides surgeons with a formula which can be applied to fine tune decision-making for all these patients. It uses the established Glasgow Coma Score (GCS) – a neurological scale that aims to give a reliable, objective way of assessing and recording the of a person – the age of the patient and the volume of the clot. It provides surgeons with a prognosis-based outcome;

10 x GCS – Age (years) - 0.64 x Volume (ml)

The cut-point was established as 27.672 - meaning that any patient scoring less than this figure should be operated upon to offer them the best prognosis.

Professor Mendelow added: "Our work provides a definitive guide as to when surgery is needed and when it can avoided to ensure the best treatment for patients."

More information: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Professor A David Mendelow, Dr Barbara A Gregson, Dr Elise N Rowan, Professor Gordon D Murray, Dr Anil Gholkar, Mr Patrick M Mitchell, STICH II Investigators. Lancet on-line 29th May 2013. www.thelancet.com/journals/lan… (13)60986-1/fulltext

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Fish oil supplements don't prevent recurrence of A-fib

22 hours ago

(HealthDay)—High doses of fish oil supplements won't prevent recurrence of atrial fibrillation (AF), Canadian researchers report. The study, funded by the Canadian Institutes for Health Research and the ...

User comments